Providing Answers, Support and Hope in Ohio
This is my chapter |
Reset
A new investigational therapy, GLPG3667, for adults with active lupus is beginning Phase 2 study to examine the safety, tolerability and efficacy of the treatment. The therapy is a tyrosine kinase 2 or TYK2 enzyme inhibitor, which prevents inflammation. TYK2 is a critical driver of disease in lupus.
The GALACELA trial will enroll approximately 140 adults with lupus who will receive the treatment orally once per day or placebo for 32 weeks.
Continue to follow the Lupus Foundation of America for updates on GLPG3667 as well as other lupus clinical trials.
Lupus Foundation of America, Greater Ohio Chapter
12930 Chippewa Road
Brecksville, OH 44141
There are multiple chapters near you. Select your preferred chapter.
Supporting lupus patients and advocates in Arizona.
Serving the District of Columbia, Maryland, and Northern Virginia.
Serving Kansas, Missouri, and Central & Southern Illinois
Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas
Serving Northern Illinois, Indiana, Iowa, Michigan, and Minnesota
Serving Connecticut, Massachusetts, Maine, New Hampshire, northern and central New Jersey, New York, Rhode Island, and Vermont
Serving Pennsylvania, Delaware and Southern New Jersey
Serving Houston, Beaumont, Corpus Christi, Harlingen and surrounding areas in Texas
There are multiple walks near you.
This website uses cookies to ensure you get the best experience. Learn more